A recent independent study conducted by the LMU University Hospital of Munich and published in Diagnostics compared different OCT Angiography technologies to evaluate their ability to provide reliable and reproducible biomarkers.
The results highlighted several strengths of the Intalight DREAM OCT, including:
✅ Up to 20 times higher contrast-to-noise ratio (CNR)
✅ Significantly lower background noise, enabling more reliable analysis of the foveal avascular zone (FAZ)
✅ Improved quantification of the deep capillary plexus (DCP) with superior vascular continuity
✅ More stable and reproducible vascular biomarkers
One of the key takeaways from this publication is that higher acquisition speed alone does not necessarily translate into better OCTA image quality. Increased background noise can artificially inflate vascular density measurements and potentially impact clinical interpretation.
As the Munich team concluded, the DREAM OCT provides better vascular continuity as well as more reliable quantification of the FAZ and DCP ; two critical parameters for monitoring retinal diseases such as diabetic retinopathy and age-related macular degeneration (AMD).
These findings further reinforce the position of the DREAM OCT as a reference solution for clinicians seeking high-quality imaging and robust, reproducible quantitative data.
At Medical DevEyes, we are proud to distribute this innovative technology developed by Intalight, whose performance continues to be validated through peer-reviewed scientific research.
📚 Read the full study here: https://www.mdpi.com/2075-4418/16/5/801
A valuable publication that provides important insights into OCT Angiography image quality beyond acquisition speed alone.
